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QSARAbstract In the present study, a series of monochloroacetic acid derivatives were synthesized and
characterized by physicochemical and spectral means. Antimicrobial evaluation was performed
against the Gram-positive bacteria: Staphylococcus aureus MTCC 2901, Bacillus subtilis MTCC
2063, Gram-negative bacterium: Escherichia coli MTCC 1652 and the fungal strains: Candida albi-
cansMTCC 227 and Aspergillus nigerMTCC 8189 using the tube dilution method. Results of anti-
microbial screening indicated that compounds 10 and 17 were found to be most potent against C.
albicans, having antifungal activity comparable to the standard drug ﬂuconazole. mt-QSAR models
indicated the importance of the steric parameter, molar refractivity (MR) in describing antibacterial
and antimicrobial activities and the electronic parameter, total energy (Te) in describing antifungal
activity of synthesized monochloroacetic acid derivatives.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
It has been observed that during the last 10 years many major
pathogenic bacteria and parasites have acquired resistance to-
ward chemotherapeutic agents in market. This has raised fears
that infectious diseases may once again become a major cause
of death in developing/developed countries. Now, there is a
need to give serious consideration toward the development
of novel chemotherapeutic agents to combat multi-drug resis-
tant (MDR) strains (Kulandaivelu et al., 2011).In previous papers, we described the preparation and anti-
microbial properties of derivatives of simple organic acids viz.
sorbic acid (Narasimhan et al., 2003), cinnamic acid (Narasim-
han et al., 2004), anacardic acid (Narasimhan and Dhake,
2006a), veratric acid (Narasimhan et al., 2009), myristic acid
(Narasimhan et al., 2006b), caprylic acid (Chaudhary et al.,
2008), anthranilic acid (Mahiwal et al., 2012) and dodecanoic
acid (Sarova et al., 2011). The antibacterial potential of mono-
chloroacetic acid was reported by Poth and Slattery (1947).
Monochloroacetic acid was also used for the treatment of
warts (Steele et al., 1988).
Quantitative structure–activity relationship (QSAR) studies
are indubitably of great importance in modern chemistry and
biochemistry. To obtain a signiﬁcant correlation, it is essential
that appropriate descriptors are employed, whether they are
theoretical, empirical or derived from readily available experi-
mental characteristics of structures. Many descriptors reﬂect
simple molecular properties and can thus provide insight into
S910 R. Gupta et al.the physicochemical nature of the activity under consideration
(Thakur et al., 2004).
Prompted from the above ﬁndings and in continuation of
efforts in exploring the antimicrobial potential of organic
acids (Kumar et al., 2010, 2012; Judge et al., 2012a,b; Narang
et al., 2012a,b), in the present study we hereby describe the
synthesis, antimicrobial evaluation and QSAR studies of
a series of monochloroacetic acid derivatives for the ﬁrst time.
2. Materials and methods
2.1. Instrumentation
All reagents and solvents used in study were of analytical grade
and procured locally. The progress of the reaction was moni-
tored by TLC and the products were puriﬁed through recrystal-
lization and the purity of the compounds was checked by thin
layer chromatography (TLC) performed on a silica gel G
coated plate. The spectral studies, IR and NMR were deter-
mined by standard methods. Infra red (IR) spectra were
recorded in KBr on a Perkin–Elmer spectrometer RX-I
instrument and were recorded in cm1. The 1H and 13C
NMR spectra were recorded in DMSO-d6 on a Brucker
DRX-300 FTNMR instrument. Elemental analysis was per-
formed on a Perkin–Elmer 2400 C, H, N analyzer. Mass spectra
were taken on a Waters Micromass Q-ToF Micro instrument.
2.1.1. General procedure for the synthesis of Schiff bases of
monochloroacetic acid (1–17)
Monochloroacetic acid (0.01 M) and propanol (0.01 M) were
reﬂuxed in the presence of sulfuric acid (catalyst) for 3–4 h
to yield propyl 2-chloroacetate. Propyl 2-chloroacetate
(0.01 M) was reﬂuxed with hydrazine hydrate (0.01 M) and
ethanol was taken as the solvent to obtain 2-chloroacetohyd-
razide. Reaction mixture was cooled in icecold water and kept
for evaporation. 2-Chloroacetohydrazide was further treated
with different aromatic aldehydes to yield the title compounds
(1–17). Schiff bases of monochloroacetic acid were ﬁltered,
dried and recrystallized from ethanol.
2.1.2. General procedure for the synthesis of esters of
monochloroacetic acid (18–29)
Monochloroacetic acid (0.01 M) was reﬂuxed with an appropri-
ate (different) alcohol (0.01 M) in the presence of few drops of
sulfuric acid for 3–4 h. The reaction mixture was then cooled
in icecold water and neutralized with sodium bicarbonate solu-
tion (0.5 M) followed by the extraction of ester with ether
(50 ml). The ether layer was separated which on evaporation
yielded the ester derivatives (18–29) of monochloroacetic acid.
Compound 1: IR (KBr pellets) cm1: 714 (C–Cl str., aro-
matic), 2975 (C–H Str., CH2), 1609 (C‚O str., sec. amide),
960 (N–N str., NH–N), 1718 (C‚N str., N‚CH), 3075 (C–
H str., phenyl); 1H NMR (DMSO): 7.136–7.842 (m, 4H,
ArH), 4.378 (s, 2H, CH2Cl), 8.472 (s, 1H, N‚CH).
Compound 2: IR (KBr pellets) cm1: 718 (C–Cl str., aro-
matic), 2988 (C–H Str., CH2), 1622 (C‚O str., sec. amide),
976 (N–N str., NH–N), 1718 (C‚N str., N‚CH), 3083 (C–
H str., phenyl), 1334 (C–N str., aryl tertiary amine); 1H
NMR (DMSO): 6.613–8.811 (m, 4H, ArH), 2.808 (s, 6H, N–
CH3), 9.678 (s, 1H, N‚CH).Compound 8: IR (KBr pellets) cm1: 724 (C–Cl str., acy-
clic), 2970 (C–H Str., CH2), 957 (N–N str., NH–N), 1630
(C‚O str., Sec. amide), 1246 (C–O–C str., Ar–O–CH3),
1654 (C‚N str., N‚CH), 1171 (C‚O str., phenol), 1H
NMR (DMSO): 6.632–7.347 (m, 4H, ArH), 4.328 (s, 2H,
CH2Cl), 8.415 (s, 1H, N‚CH), 1.42 (t, 3H, CH3 of OC2H5),
4.157 (m, 2H, CH3 of OC2H5).
Compound 9: IR (KBr pellets) cm1: 520 (C–Br str., phe-
nyl), 697 (C–Cl str., acyclic), 1625 (C‚N str., N‚CH), 3448
(N–H str., amide), 955 (N–N str., NH–N), 2955 (C–H Str.,
CH2), 3100 (C–H str., phenyl);
1H NMR (DMSO): 7.443–
8.355 (m, 4H, ArH), 8.669 (s, 1H, N‚CH).
Compound 16: IR (KBr pellets) cm1: 3432 (N–H str.,
amide), 1603 (C‚N str., N‚CH), 746 (C–Cl str.), 976 (N–
N str., NH–N), 2970 (C–H asym str., CH‚CH); 1H NMR
(DMSO): 7.138–7.319 (m, 5H, ArH), 6.551 (t, CH‚CH),
7.034 (s, 1H, NH), 7.500 (d, 1H, N‚CH).
Compound 17: IR (KBr pellets) cm1: 718 (C–Cl str., aro-
matic), 2982 (C–H Str., CH2), 1623 (C‚O str., sec. amide),
984 (N–N str., NH–N), 1702 (C‚N str., N‚CH), 3064 (C–
H str., phenyl), 1531 (NO2 str.);
1H NMR (DMSO): 7.893–
8.546 (m, 4H, ArH), 8.688 (s, 1H, N‚CH).
2.2. In vitro antimicrobial activity
The antimicrobial activity of the synthesized compounds was
tested against Gram-positive bacteria: Staphylococcus aureus
MTCC 2901, B. subtilis MTCC 2063, Gram-negative bacte-
rium: Escherichia coliMTCC 1652 and fungal strains: Candida
albicans MTCC 227 and Aspergillus niger MTCC 8189 using
the tube dilution method (Cappucino and Sherman, 1999).
Dilutions of test and standard compounds were prepared in
double strength nutrient broth––I.P. (bacteria) or Sabouraud
dextrose broth I.P. (fungi) (Pharmacopoeia of India, 2007).
The samples were incubated at 37C for 24 h (bacteria), at
25C for 7 d (A. niger), and at 37C for 48 h (C. albicans),
and the results were recorded in terms of minimum inhibitory
concentration (MIC).
2.3. QSAR studies
The structures of monochloroacetic acid derivatives (1–29)
were ﬁrst pre-optimized with the Molecular Mechanics Force
Field (MM+) procedure included in Hyperchem 6.03 (Hyper-
chem 6.0, 1993) and the resulting geometries were further re-
ﬁned by means of the semiempirical method PM3
(Parametric Method-3). We chose a gradient norm limit of
0.01 kcal/A for the geometry optimization. The lowest energy
structure was used for each molecule to calculate physicochem-
ical properties using TSAR 3.3 software for Windows (TSAR
3D Version 3.3, 2000). Further, the regression analysis was
performed using the SPSS software package (SPSS for Win-
dows, 1999).
3. Results and discussion
3.1. Chemistry
Monochloroacetic acid derivatives (1–29) were synthesized as
outlined in Scheme 1. Initially, propyl 2-chloroacetate was
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Comp. R R1 R2 R3 R4 R5
1. - H Cl H H H 
2. - H H -N(CH3)2 H H 
3. - OCH3 H H H H 
4. - Cl H H H H 
5. - H H H H H 
6. - H OCH3 OCH3 H H 
7. - H H OCH3 H H 
8. - H OC2H5 OH H H 
9. - H Br H H H 
10. - H OCH3 OH H H 
11. - H CH3 CH3 CH3 H 
12. - H H CHO H H 
13. - H H Br H H 
14. - H H Cl H H 
15. - H H CH3 H H 
16. - - - - - - 
17. - H NO2 H H H 
18. -CH2CH3 - - - - - 
19. -(CH2)2CH3 - - - - - 
20. Iso -(CH2)2CH3 - - - - - 
21. -(CH2)3CH3 - - - - - 
22. Iso-(CH2)3CH3 - - - - - 
23. Sec-(CH2)3CH3 - - - - - 
24. -(CH2)4CH3 - - - - - 
25. Iso-(CH2)4CH3 - - - - - 
26. -(CH2)6CH3 - - - - - 
27. -(CH2)7CH3 - - - - - 
28. - - - - - 
29. H2C - - - - - 
Scheme 1 Scheme for the synthesis of monochloroacetic acid derivatives.
Synthesis, antimicrobial evaluation and QSAR studies of monochloroacetic acid derivatives S911synthesized using the reaction between propanol and
monochloroacetic acid in the presence of sulfuric acid. The
ester was then reacted with hydrazine hydrate in the presence
of ethanol and yielded 2-chloroacetohydrazide. The Schiff
bases (1–17) were then synthesized by the reaction of 2-chloro-
acetohydrazide and the corresponding aromatic aldehydes in
the presence of small amount of glacial acetic acid. Ester deriv-
atives (18–29) were synthesized by the reaction of monochloro-
acetic acid with different alcohols in the presence of sulfuric
acid. The physicochemical properties of the synthesized com-
pounds are presented in Table 1. The structures of the synthe-
sized compounds were also conﬁrmed by the IR and 1H and
13C NMR spectral analysis which were in full agreement with
their structures. Further, the elemental analysis and mass spec-
tra also supported the formation of title compounds. 13C
NMR, Mass and elemental analysis data of synthesized com-
pounds are given in Table 2.3.2. In-vitro antimicrobial activity
The synthesized monochloroacetic acid derivatives were evalu-
ated for their in vitro antibacterial activity against S. aureus,
B. subtilis, E. coli and antifungal activity against C. albicans
and A. niger by the tube dilution method and the results of
antimicrobial activity are given in Table 3. From the recorded
pMIC values, it was observed that compound 8 was found to
be most active against B. subtilis and E. coli, having pMICbs
and pMICec values 1.61 and 1.91 respectively. The compounds
9 and 13 were found to be most active against S. aureus having
a pMIC value of 1.64. Compound 11 was found to be most ac-
tive against A. niger having a pMIC value of 1.66. The com-
pounds 10 and 17 were found to be most potent against C.
albicans, whose pMIC value (2.19) was comparable to the stan-
dard drug ﬂuconazole (pMICaf = 2.64) and may be taken as
lead compounds for the development of novel antifungal agents.
Table 1 Physicochemical properties of monochloroacetic acid derivatives (1–29).
Comp. M. Formula M. Wt. M.P./B.P.a (C) Rf Value* % Yield
1 C9H8Cl2N2O 231.0 110–115 0.27 86.58
2 C11H14ClN3O 239.7 80–85 0.28 79.40
3 C10H11ClN2O2 226.6 120–125 0.54 37.14
4 C9H8Cl2N2O 231.0 110–115 0.27 86.58
5 C9H9ClN2O 196.6 60–65 0.61 43.87
6 C11H13ClN2O3 256.6 135–140 0.65 32.81
7 C10H11ClN2O2 226.6 150–155 0.54 34.95
8 C11H13ClN2O3 256.6 160–165 0.30 29.29
9 C9H8BrClN2O 275.5 135–140 0.78 50.18
10 C10H11ClN2O3 242.6 130–135 0.77 53.97
11 C12H15ClN2O4 286.7 135–140 0.88 69.23
12 C10H9ClN2O2 224.6 205–215 0.31 44.64
13 C9H8BrClN2O 273.5 200–205 0.31 15.01
14 C9H8Cl2N2O 231 125–130 0.43 73.59
15 C10H11ClN2O 210.6 115–120 0.36 47.14
16 C11H11ClN2O 222.6 90–95 0.34 50.45
17 C9H8ClN3O3 241.6 50–55 0.65 16.38
18 C4H7ClO2 122.5 45–50
a 0.49 7.81
19 C5H9ClO2 136.5 55–60
a 0.30 33.88
20 C5H9ClO2 136.5 60–65
a 0.56 37.54
21 C6H11ClO2 150.6 65–70
a 0.33 95.19
22 C6H11ClO2 150.6 70–75
a 0.80 94.06
23 C6H11ClO2 150.6 72–77
a 0.46 65.33
24 C7H13ClO2 164.6 75–80
a 0.50 82.82
25 C7H13ClO2 164.6 77–82
a 0.83 86.9
26 C9H17ClO2 192.6 85–90
a 0.53 76.70
27 C10H19ClO2 206.7 88–93
a 0.41 94.30
28 C8H13ClO2 176.6 90–95
a 0.73 93.30
29 C9H9ClO2 184.6 100–105
a 0.46 71.51
* TLC mobile phase – benzene.
a b.p.
S912 R. Gupta et al.3.3. SAR (structure–activity relationship) studies
From the antimicrobial screening results of synthesized mono-
chloroacetic acid derivatives, the following structure–activity
relationship (SAR) can be derived:
1. The esters of monochloroacetic acid are less active as
compared to Schiff bases of monochloroacetic acid.
2. The compounds with electron releasing groups (OH,
OC2H5, OCH3) are more active against B. subtilis, Esch-
erichia coli and Aspergillus niger as evidenced by the
high activity of compounds 8 and 11.
3. The compounds with electron withdrawing groups (Br)
are more active against Staphylococcus aureus as evi-
denced by the high activity of compounds 9 and 13.
4. Increase in conjugation between nitrogen and phenyl
nucleus results in less antimicrobial activity as in the case
of compound 16.
5. The compounds with no substitution on phenyl ring are
having less antimicrobial activity.
The aforementioned ﬁndings are summarized in Figure 1.
3.4. QSAR study for antimicrobial activity
In order to identify the substituent effect on the antimicrobial
activity, quantitative structure–activity relationship (QSAR)
study was undertaken using a linear free energy relationshipmodel (LFER) described by Hansch and Fujita (Hansch and
Fujita, 1964). Biological activity data determined as MIC val-
ues were ﬁrst transformed into pMIC values (i.e. log MIC)
and used as dependent variables in the QSAR study (Table 3).
The different molecular descriptors selected for the present
study are listed in Table 4. The values of selected molecular
descriptors used in the QSAR study are presented in Table 5.
Our earlier studies (Kumar et al., 2012; Judge et al.,
2012a,b; Narang et al., 2012a,b) indicated that the multi-target
QSAR (mt-QSAR) models are better than one-target QSAR
(ot-QSAR) models in describing the antimicrobial activity.
So, in the present study we have developed multi-target QSAR
models to describe the antimicrobial activity of synthesized
monochloroacetic acid derivatives.
According to the ot-QSAR models one should use ﬁve dif-
ferent equations with different errors to predict the activity of
a new compound against the ﬁve microbial species. The ot-
QSAR models, which are almost in the whole literature, be-
come impractical to use when we have to predict each com-
pound’s results for more than one target. In these cases we
have to develop one ot-QSAR for each target. However, very
recently the interest has increased in the development of mul-
ti-target QSAR (mt-QSAR) models. In opposition to ot-
QSAR, the mt-QSAR model is a single equation that considers
the nature of molecular descriptors which are common and
essential for describing the antibacterial and antifungal activi-
ties (Gonzalez-Diaz et al., 2007, 2008; Cruz-Monteagudo et al.,
2007; Gonzalez-Diaz and Prado-Prado, 2008).
Table 2 Spectral and elemental analyses data of the synthesized compounds (1–29).
Comp. 13C NMR (DMSO) Mass Elemental analysis (%)
C (Found) H (Found) N (Found)
1 135.5, 127.1, 130.7, 131.0, 134.5, 129.2, 45.5, 168.4, 143.2 MS ES+(ToF): m/z 232 [M++1] 46.78 (46.72) 3.49 (3.44) 12.12 (12.17)
2 123.0, 130.3, 114.7, 151.5, 114.1, 130.0, 40.5, 40.5, 45.3, 168.2, 143.1 MS ES+(ToF): m/z 241 [M++1] 55.12 (55.16) 5.89 (5.92) 17.53 (17.47)
3 116.5, 130.3, 121.0, 132.4, 114.2, 160.8, 55.6, 45.3, 168.1, 143.4 MS ES+(ToF): m/z 228 [M++1] 52.99 (52.95) 4.89 (4.91) 12.36 (12.33)
4 133.6, 130.5, 127.3, 129.8, 132.2, 134.1, 45.4, 168.0, 143.1 MS ES+(ToF): m/z 232 [M++1] 46.78 (46.81) 3.49 (3.53) 12.12 (12.16)
5 133.9, 129.5, 128.7, 131.3, 128.6, 129.0, 45.4, 168.1, 143.0 MS ES+(ToF): m/z 198 [M++1] 54.97 (54.99) 4.61 (4.66) 14.25 (14.30)
6 127.3, 122.8, 115.2, 152.5, 149.7, 114.8, 45.0, 168.1, 143.3, 56.5, 56.5 MS ES+(ToF): m/z 258 [M++1] 51.47 (51.53) 5.10 (5.14) 10.91 (10.88)
7 126.5, 130.3, 114.0, 163.1, 114.7, 130.3, 45.5, 168.1, 143.2, 55.6 MS ES+(ToF): m/z 228 [M++1] 52.99 (52.95) 4.89 (4.84) 12.36 (12.33)
8 127.2, 122.5, 116.9, 148.4, 148.7, 114.5, 45.6, 168.3, 143.2, 65.3, 14.4 MS ES+(ToF): m/z 258 [M++1] 51.47 (51.53) 5.10 (5.06) 10.91 (10.88)
9 136.2, 128.5, 131.3, 134.0, 123.4, 132.5, 45.1, 168.3, 143.4 MS ES+(ToF): m/z 277 [M++1] 39.23 (39.27) 2.93 (2.98) 10.17 (10.22)
10 126.0, 127.8, 115.6, 158.7, 126.6, 130.5, 45.1, 168.1, 143.0, 14.3 MS ES+(ToF): m/z 244 [M++1] 49.50 (49.47) 4.57 (4.60) 11.54 (11.51)
11 130.9, 126.2, 136.7, 138.5, 136.6, 126.8, 45.5, 168.1, 143.2, 18.0, 11.4,
18.3
MS ES+(ToF): m/z 288 [M++1] 50.27 (50.23) 5.27 (5.25) 9.77 (9.82)
12 139.9, 129.5, 130.3, 139.4, 130.1, 129.9, 45.0, 168.2, 143.1, 191.3 MS ES+(ToF): m/z 226 [M++1] 53.47 (53.45) 4.04 (4.08) 12.47 (12.52)
13 132.9, 131.6, 131.4, 125.2, 131.5, 131.7, 45.0, 168.0, 143.3 MS ES+(ToF): m/z 275 [M++1] 39.23 (39.28) 2.93 (2.99) 10.17 (10.13)
14 131.6, 130.5, 129.3, 136.8, 129.2, 130.4, 45.5, 168.1, 143.00 MS ES+(ToF): m/z 232 [M++1] 46.78 (46.77) 3.49 (3.44) 12.12 (12.26)
15 130.5, 129.3, 129.0, 140.9, 129.1, 129.5, 45.6, 168.1, 143.3, 24.5 MS ES+(ToF): m/z 212 [M++1] 57.01 (57.03) 5.26 (5.29) 13.30 (13.25)
16 137.7, 126.2, 139.3, 135.0, 126.5, 128.4, 128.2, 128.4, 126.7, 45.1, 168.0 MS ES+(ToF): m/z 224 [M++1] 59.33 (59.35) 4.98 (5.03) 12.58 (11.54)
17 134,.9 135.5, 129.4, 123.3, 148.7, 124.0, 145.3, 168.1, 143.4 MS ES+(ToF): m/z 243 [M++1] 44.74 (44.77) 3.34 (3.38) 17.39 (17.42)
18 14.3, 60.4, 40.7, 166.5 MS ES+(ToF): m/z 124 [M++1] 39.20 (39.22) 5.76 (5.72) –
19 10.1, 22.2, 66.5, 40.2, 166.6 MS ES+(ToF): m/z 138 [M++1] 43.97 (43.99) 6.64 (6.69) –
20 68.5, 23.8, 23.8, 40.6, 166.5 MS ES+(ToF): m/z 138 [M++1] 43.97 (43.99) 6.64 (6.61) –
21 64.5, 31.1, 19.2, 13.9, 40.1, 166.8 MS ES+(ToF): m/z 152 [M++1] 47.85 (47.82) 7.36 (7.39) –
22 74.3, 27.9, 19.5, 19.5, 40.3, 166.7 MS ES+(ToF): m/z 152 [M++1] 47.85 (47.89) 7.36 (7.33) –
23 73.8, 29.3, 7.9, 21.1, 40.6, 166.7 MS ES+(ToF): m/z 152 [M++1] 47.85 (47.88) 7.36 (7.32) –
24 64.3, 28.9, 28.0, 22.6, 14.3, 40.4, 166.7 MS ES+(ToF): m/z 166 [M++1] 51.07 (51.11) 7.96 (7.90) –
25 61.9, 38.5, 24.7, 22.6, 22.6, 40.2, 166.9 MS ES+(ToF): m/z 166 [M++1] 51.07 (51.10) 7.96 (7.93) –
26 64.3, 29.1, 25.7, 29.2, 31.6, 22.5, 40.6, 167.0 MS ES+(ToF): m/z 194 [M++1] 56.10 (56.13) 8.89 (8.53) –
27 64.0, 29.5, 25.9, 29.6, 31.2, 22.1, 14.3, 40.8, 167.3 MS ES+(ToF): m/z 208 [M++1] 58.10 (58.13) 9.26 (9.23) –
28 151.7, 121.5, 129.3, 125.9, 129.3, 121.5, 40.5, 163.1 MS ES+(ToF): m/z 178 [M++1] 54.40 (54.44) 7.42 (7.47) –
29 67.4, 141.3, 127.5, 129.3, 127.9, 129.3, 127.5, 40, 0.1 167.2 MS ES+(ToF): m/z 186 [M++1] 58.55 (58.52) 4.91 (4.93) –
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Table 3 Antimicrobial activity (pMIC in lM/ml) of the synthesized monochloroacetic acid derivatives (1–29).
Comp. pMICbs pMICsa pMICec pMICca pMICan pMICab pMICaf pMICam
1 1.57 1.57 1.57 2.17 1.27 1.57 1.72 1.63
2 1.28 1.58 1.58 1.88 1.28 1.48 1.58 1.52
3 1.26 1.56 1.56 1.56 1.26 1.46 1.41 1.44
4 1.57 1.57 1.87 1.87 1.27 1.67 1.57 1.63
5 1.20 1.50 1.50 1.80 1.20 1.40 1.50 1.44
6 1.31 1.61 1.61 1.61 1.31 1.51 1.46 1.49
7 1.26 1.26 1.56 1.86 1.26 1.36 1.56 1.44
8 1.61 1.61 1.91 1.91 1.31 1.71 1.61 1.67
9 1.34 1.64 1.64 1.95 1.34 1.54 1.64 1.58
10 1.29 1.59 1.59 2.19 1.29 1.49 1.74 1.59
11 1.36 1.36 1.66 1.96 1.66 1.46 1.81 1.60
12 1.56 1.25 1.56 1.86 1.25 1.46 1.56 1.50
13 1.34 1.64 1.64 1.95 1.34 1.54 1.64 1.58
14 1.27 1.57 1.57 1.57 1.27 1.47 1.42 1.45
15 1.53 1.53 1.53 1.83 1.23 1.53 1.53 1.53
16 1.25 1.55 1.55 1.55 1.25 1.45 1.40 1.43
17 1.29 1.29 1.59 2.19 1.29 1.39 1.74 1.53
18 0.99 1.29 0.99 1.29 0.99 1.09 1.14 1.11
19 1.04 1.34 1.34 1.64 1.04 1.24 1.34 1.28
20 1.04 1.04 1.34 1.94 1.04 1.14 1.49 1.28
21 1.38 1.38 1.38 1.68 1.08 1.38 1.38 1.38
22 1.08 1.38 1.08 1.68 1.08 1.18 1.38 1.26
23 1.38 1.08 1.38 1.98 0.78 1.28 1.38 1.32
24 1.12 1.12 1.42 2.02 1.12 1.22 1.57 1.36
25 1.12 1.42 1.42 1.42 1.12 1.32 1.27 1.30
26 1.19 1.49 1.49 1.79 1.19 1.39 1.49 1.43
27 1.22 1.52 1.52 1.82 1.22 1.42 1.52 1.46
28 1.18 1.48 1.48 1.79 1.18 1.38 1.48 1.42
29 1.17 1.47 1.47 1.77 1.47 1.37 1.62 1.47
SD 0.17 0.17 0.18 0.22 0.16 0.15 0.15 0.13
Std. 2.61a 2.61a 2.61a 2.64b 2.64b – – –
Comp. = compound number, SD = standard deviation, Std. = standard drugs. i.e. Staphylococcus aureus, B. subtilis, Escherichia coli, Candida
albicans and Aspergillus niger, respectively.
a Ciproﬂoxacin.
b Fluconazole pMICsa, pMICbs, pMICec, pMICca and pMICan = log MIC in lM/ml against different microorganisms.
ClCH2COOH
ClCH2COOR
ClCH2CONHN=CH
Less Antimicrobial 
Activity
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the antimicrobial activity
R
Electron releasing 
groups
 (OH, OC2H5, OCH3)
Electron withdrawing 
groups (Br)
No substitution
Increase antimicrobialal activity 
against B. subtilis, E. coli 
and A. niger
Increase antimicrobial activity 
against S. aureus
Less antimicrobial activity
Figure 1 Structural requirements for the antimicrobial activity of synthesized monochloroacetic acid derivatives.
S914 R. Gupta et al.In light of the above, we have attempted to develop three
different mt-QSAR models viz. mt-QSAR model for describ-
ing the antibacterial activity of the synthesized compounds
against S. aureus, B. subtilis and E. coli, mt-QSAR model
for describing the antifungal activity of the synthesized com-
pounds against C. albicans and A. niger as well as a com-mon mt-QSAR model for describing the antimicrobial
(overall antibacterial and antifungal) activity of the synthe-
sized compounds against all the above mentioned
microorganisms.
In order to develop mt-QSAR models, initially we calcu-
lated the average antibacterial, antifungal and antimicrobial
Table 4 QSAR descriptors used in the study.
S.No. QSAR descriptor Type
1 log P Lipophilic
2 Zero order molecular connectivity index (0v) Topological
3 First order molecular connectivity index (1v) Topological
4 Second order molecular connectivity index (2v) Topological
5 Valence zero order molecular connectivity index (0vv) Topological
6 Valence ﬁrst order molecular connectivity index (1vv) Topological
7 Valence second order molecular connectivity index (2vv) Topological
8 Kier’s alpha ﬁrst order shape index (ja1) Topological
9 Kier’s alpha second order shape index (ja2) Topological
10 Kier’s ﬁrst order shape index (j1) Topological
11 Randic topological index Topological
12 Balaban topological index Topological
13 Wiener’s topological index Topological
14 Kier’s second order shape index (j2) Topological
15 Ionization potential Electronic
16 Dipole moment (l) Electronic
17 Energy of the highest occupied molecular orbital (HOMO) Electronic
18 Energy of the lowest unoccupied molecular orbital (LUMO) Electronic
19 Total energy (Te) Electronic
20 Nuclear Energy (Nu. E) Electronic
21 Molar refractivity (MR) Steric
Table 5 Values of selected descriptors used in the QSAR study.
Comp. log P MR 0v 0vv j1 ja1 J Te LUMO HOMO l
1 1.53 56.19 10.27 8.81 13.00 12.76 3.31 2641.87 0.45 9.12 3.90
2 1.17 64.98 11.68 9.85 15.00 14.43 3.29 2813.52 0.04 9.06 3.63
3 1.85 58.79 11.10 9.05 13.07 12.24 2.06 2858.73 0.18 8.71 2.16
4 2.62 57.13 10.39 8.84 12.07 11.57 1.98 2743.10 0.35 9.22 1.79
5 2.10 52.33 9.52 7.72 11.08 10.29 1.86 2383.08 0.29 9.01 1.22
6 1.60 65.25 12.67 10.38 15.06 14.19 2.07 3334.67 0.33 8.55 1.73
7 0.15 57.36 10.81 8.81 14.00 13.43 3.06 2757.59 0.33 9.14 4.37
8 1.91 65.23 12.67 10.13 15.06 14.19 2.04 3335.22 0.34 8.73 3.36
9 2.90 59.95 10.39 9.64 12.07 11.76 1.91 2722.45 0.52 9.19 2.70
10 1.57 60.48 11.97 9.42 14.06 13.20 2.02 3179.20 0.37 8.74 2.40
11 1.35 71.71 14.25 11.71 17.05 16.15 2.23 3810.27 0.39 8.81 1.58
12 1.78 58.92 11.10 8.63 13.07 11.95 1.92 2830.93 0.89 9.28 4.47
13 1.20 58.52 10.10 9.40 13.00 12.95 2.99 2621.36 0.16 9.63 5.54
14 2.62 57.13 10.39 8.84 12.07 11.57 1.90 2742.96 0.55 9.05 3.86
15 2.57 57.37 10.39 8.64 12.07 11.29 1.90 2538.72 0.30 8.85 3.21
16 2.51 62.57 10.93 8.88 13.07 12.02 1.79 2666.24 0.52 8.72 1.08
17 2.06 59.65 11.97 8.91 14.06 12.84 1.99 3213.92 1.14 9.59 7.21
18 0.80 26.91 5.70 4.93 7.00 6.92 2.83 1623.90 0.73 11.30 2.33
19 1.27 31.44 6.41 5.63 8.00 7.92 2.86 1779.77 0.30 11.24 1.68
20 1.21 31.33 6.57 5.80 8.00 7.92 3.10 1779.57 0.78 10.97 2.19
21 1.66 36.04 7.11 6.34 9.00 8.92 2.88 1935.57 0.74 11.25 2.30
22 1.67 35.91 7.28 6.50 9.00 8.92 3.06 1935.46 0.75 11.34 2.76
23 1.68 35.86 7.28 6.50 9.00 8.92 3.22 1935.29 0.39 10.90 1.68
24 2.06 40.64 7.82 7.05 10.00 9.92 2.89 2091.39 0.74 11.34 2.76
25 1.99 40.59 7.98 7.21 10.00 9.92 3.03 2091.32 0.31 11.22 1.57
26 2.85 49.84 9.23 8.46 12.00 11.92 2.90 2403.06 0.74 11.26 2.77
27 3.25 54.44 9.94 9.17 13.00 12.92 2.91 2558.90 0.74 11.22 2.84
28 2.04 43.18 8.10 7.33 9.09 9.01 1.95 2219.51 0.35 10.92 2.00
29 2.38 46.77 8.81 7.31 10.08 9.23 1.95 2290.99 0.10 9.76 2.48
Synthesis, antimicrobial evaluation and QSAR studies of monochloroacetic acid derivatives S915activities of monochloroacetic acid derivatives which are pre-
sented in Table 3.
During the regression analysis studies it was observed
that the response values of compounds 1, 3, 6 and 18 were
outside the limits of response values of other synthesizedmonochloroacetic acid derivatives. Thus, these compounds
were designated as outliers and were not involved in the data
set for QSAR model generation. In multivariate statistics, it
is common to deﬁne three types of outliers (Furusjo et al.,
2006).
Table 6 Correlation matrix for the antibacterial activity of the synthesized monochloroacetic acid derivatives (1–29).
pMICab log P MR j1 J W Te LUMO HOMO l
pMICab 1.000
log P 0.292 1.000
MR 0.790 0.116 1.000
j1 0.675 0.046 0.953 1.000
J 0.551 0.464 0.504 0.298 1.000
W 0.688 0.011 0.954 0.970 0.469 1.000
Te 0.704 0.011 0.933 0.951 0.492 0.981 1.000
LUMO 0.604 0.148 0.712 0.590 0.765 0.701 0.709 1.000
HOMO 0.722 0.040 0.852 0.741 0.644 0.808 0.775 0.815 1.000
l 0.187 0.173 0.334 0.383 0.005 0.302 0.353 0.341 0.209 1.000
Table 7 Correlation of molecular descriptors with antibacte-
rial, antifungal and antimicrobial activities of the synthesized
compounds.
Descriptors pMICab pMICaf pMICam
log P 0.292 0.077 0.172
MR 0.790 0.688 0.872
0v 0.727 0.743 0.852
0vv 0.759 0.713 0.861
1v 0.753 0.731 0.865
1vv 0.771 0.633 0.833
2v 0.749 0.728 0.861
2vv 0.746 0.568 0.786
3v 0.426 0.532 0.544
3vv 0.294 0.184 0.292
j1 0.675 0.710 0.800
j2 0.475 0.464 0.547
ja1 0.663 0.687 0.781
ja2 0.404 0.378 0.458
ja3 0.044 0.056 0.056
R 0.753 0.731 0.865
J 0.551 0.366 0.556
W 0.688 0.725 0.817
Te 0.704 0.781 0.853
Ee 0.672 0.753 0.818
Ne 0.664 0.746 0.809
SA 0.677 0.639 0.770
IP 0.722 0.575 0.772
LUMO 0.604 0.480 0.646
HOMO 0.722 0.575 0.772
S916 R. Gupta et al.1. X/Y relation outliers are substances for which the relation-
ship between the descriptors (X variables) and the depen-
dent variables (Y variables) is not the same as in the (rest
of the) training data.
2. X outliers are substances whose molecular descriptors do
not lie in the same range as the (rest of the) training data.
3. Y outliers are only deﬁned for training or test samples.
They are substances for which the reference value of
response is invalid.
As there was no difference in the activity (Table 3) as well
as the molecular descriptor range (Table 5) of these outliers
(1, 3, 6 and 18) when compared to the other monochloroacetic
acid derivatives, these outliers belong to the category of Y out-
liers (Substances for which the reference value of response is
invalid) (Furusjo et al., 2006).Preliminary analysis was carried out in terms of correla-
tion analysis. A correlation matrix constructed for antibacte-
rial activity of the synthesized compounds is presented in
Table 6. In general, high colinearity (r> 0.5) was observed
between different parameters. A high interrelationship was
observed between the topological parameter, Wiener index
(W) and the electronic parameter, total energy (Te)
(r= 0.981) and a low interrelationship was observed be-
tween the topological parameter, Balaban index (J) and
the electronic parameter, dipole moment (l) (r= 0.005).
Correlation of calculated molecular descriptors with antibac-
terial, antifungal and antimicrobial activities is presented in
Table 7.
The structural effects on variations in antibacterial activity
of the monochloroacetic acid derivatives in terms of pMICab
were examined by regression analysis with molecular parame-
ters shown in Table 5. For 25 monochloroacetic acid deriva-
tives, Eq. (1) was derived as that of the best quality using
the steric parameter, molar refractivity (MR, r= 0.790,
Table 6).
3.4.1. LR mt-QSAR model for antibacterial activity
pMICab ¼ 0:0093MRþ 0:929 ð1Þ
n ¼ 25 r ¼ 0:790 q2 ¼ 0:546 s ¼ 0:086 F ¼ 38:26
Here and thereafter, n – number of data points, r – correla-
tion coefﬁcient, q2 – cross validated r2 obtained by leave one
out method, s – standard error of the estimate and F – Fischer
statistics.
Coefﬁcient of MR in Eq. (1) is positive which indicates
that the antibacterial activity of the synthesized compounds
is positively correlated to molar refractivity (MR) i.e. anti-
bacterial activity of synthesized compounds will increase
with an increase in the value of MR. This is evidenced by
the antibacterial activity data of the synthesized compounds
(Table 3) and their MR values (Table 5). Compound 8 hav-
ing a high MR value of 65.23 (Table 5) has maximum
antibacterial activity (pMICab = 1.71, Table 3) and com-
pound 18 having a minimum MR value of 26.91 (Table 5)
has minimum antibacterial activity (pMICab = 1.09,
Table 3).
In search of a better QSAR model, we coupled molar
refractivity (MR) with log P, which yielded a better QSAR
model for antibacterial activity (Eq. (2)) having improved r
and q2 values.
Table 8 Observed, predicted and residual antimicrobial activities of the synthesized compounds obtained by developed QSAR
models.
Comp. pMICab pMICaf pMICam
Obs. Pre. Res. Obs. Pre. Res. Obs. Pre. Res.
1 1.57 1.44 0.13 1.72 1.55 0.17 1.63 1.50 0.13
2 1.48 1.50 0.02 1.58 1.59 0.01 1.52 1.57 0.05
3 1.46 1.47 0.01 1.41 1.59 0.18 1.44 1.52 0.08
4 1.67 1.49 0.18 1.57 1.57 0.00 1.63 1.50 0.13
5 1.40 1.42 0.02 1.50 1.50 0.00 1.44 1.46 0.02
6 1.51 1.52 0.01 1.46 1.69 0.23 1.49 1.58 0.09
7 1.36 1.39 0.03 1.56 1.57 0.01 1.44 1.51 0.07
8 1.71 1.53 0.18 1.61 1.69 0.08 1.67 1.58 0.09
9 1.54 1.53 0.01 1.64 1.57 0.07 1.58 1.53 0.05
10 1.49 1.48 0.01 1.74 1.66 0.08 1.59 1.53 0.06
11 1.46 1.57 0.11 1.81 1.79 0.02 1.60 1.63 0.03
12 1.46 1.47 0.01 1.56 1.59 0.03 1.50 1.52 0.02
13 1.54 1.44 0.10 1.64 1.55 0.09 1.58 1.52 0.06
14 1.47 1.49 0.02 1.42 1.57 0.15 1.45 1.50 0.05
15 1.53 1.49 0.04 1.53 1.53 0.00 1.53 1.51 0.02
16 1.45 1.53 0.08 1.40 1.56 0.16 1.43 1.55 0.12
17 1.39 1.49 0.10 1.74 1.67 0.07 1.53 1.53 0.00
18 1.09 1.14 0.05 1.14 1.35 0.21 1.11 1.24 0.13
19 1.24 1.20 0.04 1.34 1.38 0.04 1.28 1.28 0.00
20 1.14 1.20 0.06 1.49 1.38 0.11 1.28 1.28 0.00
21 1.38 1.26 0.12 1.38 1.41 0.03 1.38 1.32 0.06
22 1.18 1.26 0.08 1.38 1.41 0.03 1.26 1.32 0.06
23 1.28 1.26 0.02 1.38 1.41 0.03 1.32 1.32 0.00
24 1.22 1.32 0.10 1.57 1.44 0.13 1.36 1.36 0.00
25 1.32 1.31 0.01 1.27 1.44 0.17 1.30 1.36 0.06
26 1.39 1.43 0.04 1.49 1.50 0.01 1.43 1.44 0.01
27 1.42 1.49 0.07 1.52 1.53 0.01 1.46 1.48 0.02
28 1.38 1.34 0.04 1.48 1.47 0.01 1.42 1.38 0.04
29 1.37 1.39 0.02 1.62 1.48 0.14 1.47 1.41 0.06
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pMICab ¼ 0:0403 log Pþ 0:0091MRþ 0:867 ð2Þ
n ¼ 25 r ¼ 0:816 q2 ¼ 0:572 s ¼ 0:083 F ¼ 21:87Observed pMICab
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Figure 2 Plot of observed pMICab against predicted pMICab by
Eq. (2).log P is one of the key determinants of pharmacokinetic
properties. Knowing the exact values for log P, it is possible
to predict the inhibitory activity of the drugs (Podunavac-
Kuzmanovic et al., 2008). log P is the logarithm of the ratio
of the concentrations of the un-ionized solute in two solvents,
which is calculated according to the following equation, where
o is octanol and w is un-ionized water.
log Po=w ¼ logð½soluteo=½solutewÞ
The hydrophobic effect is the major driving force for the
binding of drugs to their receptor targets in pharmacodynam-
ics, and is based on the log P contribution of each atom. Each
atom in a molecule contributes to the log P by the amount of
its atomic parameter multiplied by the degree of exposure to
the surrounding solvent (Park et al., 2008).
The QSAR model expressed by Eq. (2) was cross validated
by its high q2 value (q2 = 0.572) obtained by the leave one out
(LOO) method. The value of q2 greater than 0.5 is the basic
requirement for qualifying a QSAR model to be a valid one
(Golbraikh and Tropsha, 2002). As the observed and predicted
antibacterial activity values are close to each other (Table 8),
the mt-QSAR model for antibacterial activity (Eq. (2)) is a va-
lid one. The plot of predicted pMICab against observed pMI-
Cab (Figure 2) also favors the developed model expressed by
Eq. (2). Further, the plot of observed pMICab vs residual pMI-
Cab (Figure 3) indicated that there was no systemic error in
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Figure 3 Plot of observed pMICab against predicted pMICab by
Eq. (2).
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Figure 5 Plot of observed pMICam against residual pMICam by
Eq. (4).
S918 R. Gupta et al.model development as the propagation of error was observed
on both sides of zero (Kumar et al., 2007).
Results of the correlation of calculated molecular descrip-
tors with antifungal activity of synthesized compounds (Ta-
ble 7) indicated that the electronic parameter, total energy
(Te) was the most dominating descriptor for the antifungal
activity of synthesized compounds. So, the QSAR model for
the antifungal activity of monochloroacetic acid derivatives
was developed by using the electronic parameter, total energy
(Te) (r= 0.781, Table 7, Eq. (3)).
3.4.3. LR mt-QSAR model for antifungal activity
pMICaf ¼ 0:00020Teþ 1:02 ð3Þ
n ¼ 25 r ¼ 0:781 q2 ¼ 0:547 s ¼ 0:084 F ¼ 35:95
The coefﬁcient of Te is negative (Eq. (3)), which indicates a
negative correlation between the antifungal activity value of
the synthesized compounds and their Te values i.e. theObserved pMICam
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Figure 4 Plot of observed pMICam against predicted pMICam by
Eq. (4).antifungal activity of synthesized compounds will decrease
with increase in their Te values and vice versa (Tables 3 and 5).
The mt-QSAR model of antimicrobial activity (Eq. (4)) de-
picted the importance of the steric parameter, molar refractiv-
ity (MR) in describing the antimicrobial activity of the
synthesized compounds.
3.4.4. LR mt-QSAR model for antimicrobial activity
pMICam ¼ 0:0087MRþ 1:0079 ð4Þ
n ¼ 25 r ¼ 0:872 q2 ¼ 0:720 s ¼ 0:058 F ¼ 72:87
As in the case of antibacterial activity, coefﬁcient of MR in
Eq. (4) is positive which indicates that the antimicrobial activ-
ity of the synthesized compounds is positively correlated to
molar refractivity (MR) i.e. antimicrobial activity of synthe-
sized compounds will increase with an increase in the value
of MR. This is evidenced by the antimicrobial activity data
of the synthesized compounds (Table 3) and their MR values
(Table 5).
The QSAR models expressed by Eqs. (3) and (4) were cross
validated by their high q2 values (q2 = 0.547 and 0.720, respec-
tively) obtained by leave one out (LOO) method. The value of
q2 greater than 0.5 is the basic requirement for qualifying a
QSAR model to be valid one (Golbraikh and Tropsha,
2002). As the observed and predicted antifungal and antimi-
crobial activity values are close to each other (Table 8), the
mt-QSAR models for antifungal and antimicrobial activities
(Eqs. (3) and (4), respectively) are valid ones. The plot of the
predicted pMICam against observed pMICam (Figure 4) also
favors the developed model expressed by Eq. (4). Further,
the plot of observed pMICam vs residual pMICam (Figure 5)
indicated that there was no systemic error in model develop-
ment as the propagation of error was observed on both sides
of zero (Kumar et al., 2007). Further, high residual values ob-
served in case of compounds 1, 3, 6 and 18 (Table 8) justify
their removal as outliers.
Generally for QSAR studies, the biological activities of
compounds should span 2–3 orders of magnitude. But in the
present study the range of antimicrobial activities of the
Synthesis, antimicrobial evaluation and QSAR studies of monochloroacetic acid derivatives S919synthesized compounds is within one order of magnitude. This
is in accordance with results suggested by Bajaj et al. (2005)
who stated that the reliability of the QSAR model lies in its
predictive ability even though the activity data are in the nar-
row range (Bajaj et al., 2005). When biological activity data lie
in the narrow range, the presence of minimum standard devi-
ation of the biological activity justiﬁes its use in QSAR studies
(Narasimhan et al., 2007). The minimum standard deviation
(Table 3) observed in the antimicrobial activity data justiﬁes
its use in QSAR studies.
4. Conclusion
In the present study, a series of monochloroacetic acid deriv-
atives (1–29) were synthesized in appreciable yield and char-
acterized by physicochemical as well as spectral means. The
spectral data were found in agreement with the assigned
molecular structures. Results of antimicrobial studies indi-
cated that in general, Schiff bases were found to be more ac-
tive as compared to esters. The compounds with electron
releasing groups were found to be more active against B.
subtilis, E. coli and A. niger and the compounds with elec-
tron withdrawing groups were found to be more active
against S. aureus. mt-QSAR models [Eqs. (1)–(4)] indicated
the importance of the steric parameter, molar refractivity
(MR) in describing antibacterial activity and antimicrobial
activity and the electronic parameter, total energy (Te) in
describing the antifungal activity of the synthesized mono-
chloroacetic acid derivatives.
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